Seres Therapeutics (MCRB) Other Non Operating Income (2016 - 2026)
Seres Therapeutics (MCRB) posted Other Non Operating Income of $669000.0 for Q1 2026, down 73.24% sequentially from $2.5 million in Q4 2025, and down 90.6% YoY from $7.1 million in Q1 2025.
Seres Therapeutics (MCRB) Other Non Operating Income (2016 - 2026) Analysis & Trends
Seres Therapeutics has reported Other Non Operating Income for 10 years, with the latest figure at $669000.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 90.6% year-over-year to $669000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.3 million (up 249.87% YoY) and the FY2025 annual result came in at $16.8 million, up 218.77% from the prior year.
- Other Non Operating Income retreated to $669000.0 in Q1 2026 per MCRB's latest filing, from $2.5 million in the prior quarter.
- Over five years, Other Non Operating Income peaked at $7.1 million in Q1 2025 and troughed at -$22.5 million in Q3 2024.
- A 5-year average of $197823.5 and a median of $505000.0 in 2024 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2023 and 2024: Other Non Operating Income surged 3127.27% in 2023, then slumped 2353.95% in 2024.
- Over 5 years, Other Non Operating Income stood at -$23000.0 in 2022, then surged by 1560.87% to $336000.0 in 2023, then soared by 2006.25% to $7.1 million in 2024, then slumped by 64.67% to $2.5 million in 2025, then slumped by 73.24% to $669000.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $669000.0, $2.5 million, and $2.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Seres Therapeutics | 43.87 Mn | 43.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 673,000.00 |
| Mar 31, 2026 | 669,000.00 |
| Dec 31, 2025 | 2.50 Mn |
| Sep 30, 2025 | 2.84 Mn |
| Jun 30, 2025 | 4.30 Mn |
| Mar 31, 2025 | 7.12 Mn |
| Dec 31, 2024 | 7.08 Mn |
| Sep 30, 2024 | -22.52 Mn |
| Jun 30, 2024 | 1.45 Mn |
| Mar 31, 2024 | 505,000.00 |
| Dec 31, 2023 | 336,000.00 |
| Sep 30, 2023 | 999,000.00 |
| Jun 30, 2023 | -1.51 Mn |
| Mar 31, 2023 | 310,000.00 |
| Dec 31, 2022 | -23,000.00 |
| Sep 30, 2022 | -33,000.00 |
| Jun 30, 2022 | -304,000.00 |
| Mar 31, 2022 | -345,000.00 |
| Dec 31, 2021 | -316,000.00 |
| Sep 30, 2021 | -35,000.00 |